Bristol's Abatacept Launch Supply Limited Until FDA Clears Contract Facility
This article was originally published in The Pink Sheet Daily
Executive Summary
Company faces the possibility of nearly 12 months of limited supply of the rheumatoid arthritis therapy until third-party manufacturer Lonza is approved by FDA, which could occur in mid-2006. Bristol completed the abatacept rolling BLA at the end of March and has requested a priority review.